Etherna
LNP-based nucleic acid drug delivery
etherna image


Lipid nanoparticles (LNPs) are advanced carriers that protect and deliver nucleic‑acid therapeutics to their intended site of action. Their design determines whether a therapy reaches the right cells, achieves efficient expression, and maintains a strong safety profile. At etherna, we treat design as a tailored engineering process, not a one‑size‑fits‑all solution.

Using proprietary ionizable lipid libraries and advanced conjugation strategies, we create LNPs that match the specific needs of each payload, indication, and route of administration. This enables precise control over targeting, biodistribution, and overall performance.

A universal LNP doesn’t exist, each application demands customized design.

How We Engineer Fit-for-Purpose LNPs!

Customized LNPs are key to advancing nucleic-acid-based medicines for both prophylactic and therapeutic use.
We have built deep expertise and a dedicated experimental framework to design and optimize LNPs for specific
therapeutic applications.

Ionizable Lipid

Our proprietary ionizable lipid library comprises more than 2,500 distinct lipids, enables precise tuning of delivery systems, including intrinsic liver de-targeting capabilities.

Conjugation Strategy

We apply advanced conjugation strategies to engineer targeted lipid nanoparticles (LNPs), using site-specific methods such as VHH nanobody conjugation to enhance targeting activity and achieve highly selective receptor binding.

Versatile Payload

Our platform is designed to support the encapsulation of a wide range of nucleic acid payloads. With deep expertise across multiple cargo types, including pDNA, mcDNA, circRNA, siRNA, and small ASOs, we ensure flexibility across diverse therapeutic applications.

Optimized LNPs

To further optimize performance, we tailor LNP compositions to the intended application, maximizing activity while maintaining a strong safety profile.

PEG Alternatives

We actively develop and evaluate PEG alternatives through proprietary, bio-inspired polymer-lipid conjugates, improving LNP stability both during storage and in vivo delivery.

Etherna
Available LNP platforms

Our LNP platforms are differentiated by their targeting properties, biodistribution profiles, and payload compatibility, providing tailored solutions for diverse nucleic‑acid modalities.

IV delivery

Genetic diseases &
Gene editing

Targeted LNP delivery engineered for efficient in vivo gene editing in Hematopoietic stem cells

IV delivery

Immuno-oncology &
Autoimmune diseases

Precision LNP delivery enabling ex vivo and in vivo T‑cell reprogramming for immuno‑oncology and autoimmune applications

IV Delivery

Liver diseases, secreted factors & Gene editing

Clinically aligned LNP delivery optimized for durable hepatic expression and repeat dosing

IV delivery

Tolerizing vaccine for autoimmune diseases

Immune‑silent LNPs designed to induce antigen‑specific immune tolerance in autoimmune disease

IM delivery

Infectious diseases
Prophylactic vaccine

Immune‑stimulatory LNP platform optimized for intramuscular vaccine delivery and robust antibody responses

IT delivery

Intratumoral immunomodulation Immuno-oncology

Localized intratumoral LNP delivery platform for targeted immune activation in cancer

Etherna
Our strengths

“We combine deep scientific expertise, tailored engineering, and world‑class manufacturing to accelerate the development of high‑performing LNPs.”

Comprehensive
Our diverse portfolio of LNP formulations supports a wide spectrum of therapeutic applications from prophylactic and cancer vaccines to gene therapy, protein replacement, and beyond. This breadth allows partners to select the optimal delivery system for their modality and target tissue.

Customizable
We engineer LNPs with precision. Leveraging proprietary ionizable lipid libraries, specialized conjugation strategies, and an advanced experimental framework, we develop fit‑for‑purpose LNPs tailored to each payload, indication, and route of administration.

World Class facilities
Our state‑of‑the‑art LNP manufacturing sites in Ghent and Niel, Belgium, support the seamless transition from research to production. We deliver high‑quality LNPs for preclinical studies and scale up to GMP‑ready processes, ensuring quality, reliability and consistency at every stage.

etherna image
Etherna
Contact us

Contact us with any queries or for pricing information.